Eisai
Eisai Co., Ltd., commonly referred to as Eisai, is a prominent global pharmaceutical company headquartered in Japan. Established in 1941, Eisai has made significant strides in the healthcare industry, focusing on the discovery, development, and marketing of innovative medicines. With major operational regions across Asia, Europe, and North America, the company is dedicated to addressing unmet medical needs, particularly in neurology and oncology. Eisai's core products include treatments for Alzheimer's disease and various cancers, distinguished by their commitment to patient-centric solutions. The company has achieved notable recognition for its research and development efforts, positioning itself as a leader in the pharmaceutical sector. With a strong emphasis on ethical practices and collaboration, Eisai continues to enhance its market presence while striving to improve the quality of life for patients worldwide.
DitchCarbon Score
How does Eisai's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eisai's score of 23 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Eisai's reported carbon emissions
Eisai, headquartered in Japan (JP), has set ambitious climate commitments aimed at significantly reducing its greenhouse gas (GHG) emissions. Although specific emissions data for the most recent year is not available, the company has established clear reduction targets for the near future. Eisai aims to reduce its Scope 1 and Scope 2 GHG emissions by 55% by fiscal 2030, using fiscal 2019 as the base year. Additionally, the company plans to cut its Scope 3 emissions (specifically Category 1) by 27.5% within the same timeframe. These targets reflect Eisai's commitment to addressing its carbon footprint across all scopes of emissions. Furthermore, Eisai has set a long-term goal to achieve Net-Zero emissions by 2050, demonstrating its dedication to sustainability and climate action. These initiatives position Eisai as a proactive player in the pharmaceutical industry, aligning with global efforts to combat climate change.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eisai is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
